Dabrafenib medical insurance reimbursement scope

Dabrafenib has been included in the National Medical Insurance Category B, and the reimbursement scope of this drug includes1. BRAF V600 mutation-positive unresectable or metastatic melanoma: combined with trametinib is suitable for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. 2. BRAF V600Postoperative adjuvant treatment of mutation-positive melanoma: combined with trametinib is suitable for adjuvant treatment of BRAF V600 mutation-positive stage III melanoma patients after complete resection. 3..BRAF V600mutation-positive metastatic non-small cell lung cancer: combined with trametinib is suitable for the treatment of patients with BRAF V600mutation-positive metastatic non-small cell lung cancer. If you want to get more high-quality information, you can contact Yaode. Yade will do its best to learn more about high-quality overseas drugs for you.